CliffBio
biologic

Humira

adalimumab

Loss of exclusivityMarch 2028projected — 12-year biologic exclusivity estimate
CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand nameHumira
Active ingredientadalimumab
Strength40MG/0.4ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMarch 2016
Marketing statusRx

More from AbbVie Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Humira patent cliff — loss of exclusivity March 2028 | CliffBio